ReviewPharmaceutics2020
Postbiotic-Enabled Targeting of the Host-Microbiota-Pathogen Interface: Hints of Antibiotic Decline?
Review in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Effects ofBiology · 2026Article
- A Single Key for Many Doors? Unlocking the Bio-chemical Potential of Lactobacillus bulgaricus Metabolic Postbiotic.Probiotics and antimicrobial proteins · 2026Article
- From Probiotics to Postbiotics-An Update on Their Biotherapeutic Potential and the Emerging Strategies in Human Health.International journal of molecular sciences · 2026Review
- Demystifying the role of postbiotics in inflammation mediated metabolic disorders: an updated review.Food science and biotechnology · 2026Review
- Gut Microbiota and Postbiotic Metabolites: Biotic Intervention for Enhancing Vaccine Responses and Personalized Medicine for Disease Prevention.Probiotics and antimicrobial proteins · 2026Review
- A Critical Review of Postbiotics as Promising Novel Therapeutic Agents for Clostridial Infections.Probiotics and antimicrobial proteins · 2025Review
- Indole-3-Aldehyde alleviates lung inflammation in COPD through activating Aryl Hydrocarbon Receptor to inhibit HDACs/NF-κB/NLRP3 signaling pathways.Journal of molecular medicine (Berlin, Germany) · 2025Article
- Human and gut microbiota synergy in a metabolically active superorganism: a cardiovascular perspective.Frontiers in cardiovascular medicine · 2024Review
- Role of Postbiotics in Diet-Induced Metabolic Disorders.Nutrients · 2022Review
- Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite.Journal for immunotherapy of cancer · 2022Article
- Molecular and Cellular Mechanisms Influenced by Postbiotics.International journal of molecular sciences · 2021Review
- Gut Microbial Metabolite-Mediated Regulation of the Intestinal Barrier in the Pathogenesis of Inflammatory Bowel Disease.Nutrients · 2021Review
- A Shifted Composition of the Lung Microbiota Conditions the Antifungal Response of Immunodeficient Mice.International journal of molecular sciences · 2021Article
- Article
- In the Age of Viral Pandemic, Can Ingredients Inspired by Human Milk and Infant Nutrition Be Repurposed to Support the Immune System?Nutrients · 2021Review
- Postbiotics against Pathogens Commonly Involved in Pediatric Infectious Diseases.Microorganisms · 2020Review
- Gut Microbiome and Paediatric Inflammatory Bowel Disease: Emerging Mechanistic and Therapeutic Insights Into Pathogenesis and Microbiota-Based Approaches.IET systems biologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Mismanagement of bacterial infection therapies has undermined the reliability and efficacy of antibiotic treatments, producing a profound crisis of the antibiotic drug market. It is by now clear that tackling deadly infections demands novel strategies not only based on the mere toxicity of anti-infective compounds. Host-directed therapies have been the first example as novel treatments with alternate success. Nevertheless, recent advances in the human microbiome research have provided evidence that compounds produced by the microbial metabolism, namely postbiotics, can have significant impact on human health. Such compounds target the host-microbe-pathogen interface rescuing biotic and immune unbalances as well as inflammation, thus providing novel therapeutic opportunities. This work discusses critically, through literature review and personal contributions, these novel nonantibiotic treatment strategies for infectious disease management and resistance prevention, which could represent a paradigm change rocking the foundation of current antibiotic therapy tenets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.